• Molecular NameNaloxone
  • SynonymEN 1530 Base; L-Naloxone; N-Allylnoroxymorphone; Nalossone [Dcit]; Naloxona [INN-Spanish]; Naloxone HCl; Naloxonum [INN-Latin]
  • Weight327.38
  • Drugbank_IDDB01183
  • ACS_NO465-65-6
  • Show 2D model
  • LogP (experiment)2.09
  • LogP (predicted, AB/LogP v2.0)1.54
  • pka7.9
  • LogD (pH=7, predicted)0.53
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.96
  • LogSw (predicted, AB/LogsW2.0)2.81
  • Sw (mg/ml) (predicted, ACD/Labs)2.44
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds2
  • TPSA70.0
  • StatusFDA approved
  • AdministrationIV, IM
  • PharmacologyA drug used to counter the effects of opioid overdose, for example heroin or morphine overdose. Naloxone is specifically used to counteract life-threatening depression of the central nervous system and respiratory system. Naloxone is also experimentally used in the treatment for CIPA; an extremely rare disorder (1 in 125 million) that renders one unable to feel pain.
  • Absorption_value91.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability2.0
  • Protein binding40.0
  • Volume of distribution (VD)2.1 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life1.1 h
  • ExcretionUrine, Biliary
  • Urinary ExcretionNegligible
  • Clerance22 ml/min/kg
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=286 (injected)